Jannie G. Keyser-Borst is a Dutch cancer immunologist. She became Professor at Leiden University on 16 January 2019 [1] At the Leiden University Medical Center she currently runs a research group investigating the regulation of the T cell response [2]
In 1980 she received her Master's degree in biology with chemistry at Leiden University. For the main part of her PhD she worked at the Dana–Farber Cancer Institute, Harvard Medical School in Boston, supervised by Prof. Dr. Cox P Terhorst. During this time she unraveled the structure of the CD3/T cell complex. After graduation she worked with Immunologists Dr Jan E de Vries and Dr Hergen Spits in the Netherlands. She obtained her Ph.D. degree from Leiden University in 1985. In 1987, she received a 5-year personal fellowship from The Netherlands Organization for Scientific Research.
In 1992, she became staff scientist at the Netherlands Cancer Institute and was named the head of the Division of Immunology in 2002. [3] In 1999, she was appointed professor in Experimental Oncology at the University of Amsterdam.
She received the Van Loghem career award from the Dutch Society of Immunology in 2009. [4]
In 2012, she was elected EMBO member.
In 2018 she received the Delphine Parrott award for inspiring female scientists [5] by Megan MacLeod during the West of Scotland Immunology Group showcase at the University of Glasgow
Co-stimulation is a secondary signal which immune cells rely on to activate an immune response in the presence of an antigen-presenting cell. In the case of T cells, two stimuli are required to fully activate their immune response. During the activation of lymphocytes, co-stimulation is often crucial to the development of an effective immune response. Co-stimulation is required in addition to the antigen-specific signal from their antigen receptors.
ZAP-70 is a protein normally expressed near the surface membrane of lymphocytes. It is most prominently known to be recruited upon antigen binding to the T cell receptor (TCR), and it plays a critical role in T cell signaling.
CD94, also known as killer cell lectin-like receptor subfamily D, member 1 (KLRD1) is a human gene.
CD70 is a protein that in humans is encoded by CD70 gene. CD70 is also known as a ligand for CD27.
CD5 is a cluster of differentiation expressed on the surface of T cells and in a subset of murine B cells known as B-1a. The expression of this receptor in human B cells has been a controversial topic and to date there is no consensus regarding the role of this receptor as a marker of human B cells. B-1 cells have limited diversity of their B-cell receptor due to their lack of the enzyme terminal deoxynucleotidyl transferase (TdT) and are potentially self-reactive. CD5 serves to mitigate activating signals from the BCR so that the B-1 cells can only be activated by very strong stimuli and not by normal tissue proteins. CD5 was used as a T-cell marker until monoclonal antibodies against CD3 were developed.
CD27 is a member of the tumor necrosis factor receptor superfamily. It is currently of interest to immunologists as a co-stimulatory immune checkpoint molecule, and is the target of an anti-cancer drug in clinical trials.
T-cell surface glycoprotein CD3 gamma chain is a protein that in humans is encoded by the CD3G gene.
Leukocyte immunoglobulin-like receptor subfamily B member 1 is a protein that in humans is encoded by the LILRB1 gene.
CD3e molecule, epsilon also known as CD3E is a polypeptide which in humans is encoded by the CD3E gene which resides on chromosome 11.
SH2 domain–containing protein 1A is a protein that in humans is encoded by the SH2D1A gene. It is often called SLAM-associated protein, where "SLAM" refers to signaling lymphocytic activation molecules. It is a SH2 domain–containing molecule that plays a role in SLAM signaling. A putative function is as an adaptor for Fyn and competitor of phosphatases, leading to modulation of SLAM family function. SAP has been implicated in autoimmunity, and a mutation of it is associated with X-linked lymphoproliferative disease. At least 32 disease-causing mutations in this gene have been discovered.
CD84 is a human protein encoded by the CD84 gene.
NKG2-C type II integral membrane protein or NKG2C is a protein that in humans is encoded by the KLRC2 gene. It is also known as or cluster of differentiation 159c (CD159c).
T-cell surface glycoprotein CD3 delta chain is a protein that in humans is encoded by the CD3D gene.
Signaling lymphocytic activation molecule (SLAM) is a family of genes. Homophilic binding between SLAMs is involved in cell-to-cell adhesion during antigen presentation.
In immunology, a centroblast generally refers to an activated B cell that is enlarged and is rapidly proliferating in the germinal center of a lymphoid follicle. They are specifically located in the dark zone of the germinal center. Centroblasts form from naive B cells being exposed to follicular dendritic cell cytokines, such as IL-6, IL-15, 8D6, and BAFF. Stimulation from helper T cells is also required for centroblast development. Interaction between CD40 ligand on an activated helper T cell and the B cell CD40 receptor induces centroblasts to express activation-induced cytidine deaminase, leading to somatic hypermutation, allowing the B cell receptor to potentially gain stronger affinity for an antigen. In the absence of FDC and helper T cell stimulation, centroblasts are unable to differentiate and will undergo CD95-mediated apoptosis.
Immune checkpoints are regulators of the immune system. These pathways are crucial for self-tolerance, which prevents the immune system from attacking cells indiscriminately. However, some cancers can protect themselves from attack by stimulating immune checkpoint targets.
Daniel O’Connell Griffin is an American infectious disease specialist. He is president of the nonprofit organization Parasites Without Borders.
Maria Yazdanbakhsh is a Dutch immunologist who is Professor of Cellular Immunology of Parasitic Infections and Head of the Department of Parasitology at the Leiden University Medical Center. She was elected Fellow of the European Molecular Biology Organization in 2023.
Boserolimab (MK-5890) is a monoclonal antibody in development for lung cancer. It is developed by Merck.